{"name":"OVA1 / OVA1plus","slug":"aspira","ticker":"AWH","exchange":"NYSE American","domain":"aspirawh.com","description":"Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass. It is also developing OvaMDx, a multi-marker test that combines serum proteins, clinical data, and miRNA for assessing the risk of ovarian cancer in women with an adnexal mass; EndoCheck, a protein biomarker designed to identify ovarian endometriomas; and EndoMDx for the identification of endometriosis. The company also operates Aspira Labs, a laboratory that specializes in applying biomarker-based technologies to a","hq":"Austin, TX","founded":0,"employees":"66","ceo":"Nicole Sandford","sector":"Diagnostics / Oncology","stockPrice":0.08,"stockChange":0,"stockChangePercent":0,"marketCap":"$35M","metrics":{"revenue":10000000,"revenueGrowth":10.3,"grossMargin":59.7,"rdSpend":0,"netIncome":-13094000,"cash":1769000,"dividendYield":0,"peRatio":-0.3,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2023-02-22","type":"regulatory","headline":"AWH Announces FDA Clearance for OVA1plus","summary":"AWH received FDA clearance for OVA1plus, expanding its product portfolio in the US market.","drugName":"OVA1plus","sentiment":"positive"},{"date":"2022-11-10","type":"earnings","headline":"AWH Reports Third Quarter 2022 Financial Results","summary":"AWH reported revenue growth and improved profitability in the third quarter of 2022.","drugName":"","sentiment":"positive"},{"date":"2022-08-25","type":"deal","headline":"AWH Partners with Leading Healthcare Provider to Expand OVA1plus Access","summary":"AWH partnered with a leading healthcare provider to increase access to OVA1plus in the US market.","drugName":"OVA1plus","sentiment":"positive"}],"realNews":[],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Exact Sciences","LabCorp","Quest Diagnostics"],"therapeuticFocus":["Oncology","Diagnostics"],"financials":null,"yahoo":{"currentPrice":0.08,"previousClose":0,"fiftyTwoWeekHigh":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekRange":"","fiftyDayAverage":0,"twoHundredDayAverage":0,"beta":2.01,"enterpriseValue":4047668,"forwardPE":-0.3,"priceToBook":0,"priceToSales":0,"enterpriseToRevenue":0.44,"enterpriseToEbitda":-0.25,"pegRatio":0,"ebitda":-16186000,"ebitdaMargin":-176.3,"freeCashflow":-7882375,"operatingCashflow":-12113000,"totalDebt":3376000,"debtToEquity":0,"currentRatio":0.77,"returnOnAssets":-173.1,"returnOnEquity":0,"analystRating":"","recommendationKey":"none","numberOfAnalysts":1,"targetMeanPrice":5.5,"targetHighPrice":5.5,"targetLowPrice":5.5,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":14.6,"institutionHeldPercent":4.1,"sharesOutstanding":0,"floatShares":24609973,"sharesShort":252929,"shortRatio":0.02,"shortPercentOfFloat":1.4,"epsTrailing":0,"epsForward":0,"revenuePerShare":0.65,"bookValue":0,"officers":[{"age":null,"name":"Ms. Nicolette  Possemato","title":"Senior Vice President of Human Resources"},{"age":null,"name":"Ms. Michelle  Snider","title":"Senior Vice President of Commercial Strategy & Operations"},{"age":null,"name":"Ms. Jamie L. Sullivan","title":"Chief of Staff & ARPA-H Program Director"}],"industry":"Diagnostics & Research","irWebsite":"http://phx.corporate-ir.net/phoenix.zhtml?c=121814&p=irol-IRHome","website":"https://aspirawh.com","phone":"512 519 0400"}}